Gelucire 5013 Gattefosse

Agente para enmascarar sabor.

Gelucire 5013 gattefosse. People make our name. Mulations, Gelucire® 50/13—Controlled release and increased bio- availability , Gattefossé PF , first ed., April 99, 3000 ex, 1999. Application Water dispersible surfactant, Solubilizer, Bioavailability.

It has similar surfactive properties to Gelucire® 44/14. The results revealed that the moderate amount of Gelucire 43/01 and ethyl cellulose. Peceol ™ Labrafac ™ lipophile WL 1349;.

Gelucire® 50/13 was a gift by Gattefossè (Milan, Italy). Solid state characterization, kinetic solubility, powder dissolution, stability, and pharmacokinetics were analyzed in rats. CA1 CAA CA CA1 CA A1 C A1 CA A1 CA A CA A CA A CA A C A CA A CA A1 C A1 CA A1 Authority CA Canada Prior art keywords isotretinoin pharmaceutical composition contains group consisting mixtures Prior art date Legal status (The legal status is an assumption.

Development of Solid SEDDS, III:. One excipient that has stimulated interest in lipid-based solid dispersion formulations is Gelucire 44/14 (Gattefosse Corp., St. Legal notices - Terms and condition © Gattefossé People make our name.

Single excipient formulation system:. SAXS analysis of the untreated sample shows a lamellar phase of1Å(figure2).Nosignaloftheacylglycerol fraction was detected. USB2 US11/2,363 USA USB2 US B2 US B2 US B2 US A US A US A US B2 US B2 US B2 Authority US United States Prior art keywords method isotretinoin composition group consisting selected Prior art date Legal status (The legal status is an assumption and is not a legal conclusion.

As discussed previously, even though most Gelucires have T m > 37°C, (the most frequently used for SLN/NLC formulation up to now is Gelucire 50/13), their T m after processing to colloidal dimensions is expected to be decreased, leading to only partially crystallized lipid matrix. Briefly, Precirol, 500 mg and Gelucire 50/13, at various concentrations (100, 150, 0, 250 and 650 mg) were transferred to a test tube. Particles from gas saturated solutions (PGSS) process was chosen for investigation as a manufacturing process for producing a ….

Tocopheryl propylene glycol succinate, Sucroester 15, Gelucire 50/13, and Myrj 52. This is a purified, de-oiled, and granulated soy lecithin with a high phosphatidylcholine. Single excipient formulation system:.

Gelucire 50/13 (semi-synthetic polyglycolized glycerides) was provided by Gattefosse, St.Priest, Cedex, France. Priority to BE priority Critical Application filed by Galephar M/F filed Critical Galephar M/F Priority to PCT/BE01/ priority patent/WOA1/en Assigned to GALEPHAR M/F reassignment GALEPHAR M/F ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). US564B2 US13/525,857 USA US564B2 US 564 B2 US564 B2 US 564B2 US A US A US A US 564 B2 US564 B2 US 564B2 Authority US United States Prior art keywords isotretinoin pharmaceutical composition oral pharmaceutical composition mg Prior art date.

Gelucire ® 44/14 is a. Gelucire 50/13 was provided by Gattefosse (Cedex, France) and has m.p. A stability study on samples was conducted for 3 months to evaluate the physical state of the drug and its dissolution in the formulation.

This self-emulsifying excipient that exists as a waxy semi-solid at ambient room temperature is a mixture of glyceryl and PEG 1500 esters of long-chain fatty acids and is listed in the European Pharmacopoeia as laurylmacrogolglycerides and in the. Craig, The physical characterisation of. It melts at approximately 50°C and has hydrophilic-lipophilic balance (HLB) value of 13 6, 7.

Product description Gelucire® 50/13 (stearoyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Solubilizer for poorly-soluble APIs and bioavailability enhancer. ABITEC) were developed using stearoyl polyoxyl glycerides (Acconon®C-50, ABITEC and Gelucire®50/13, Gattefosse) as both solidifying and emulsifying agents.

Precirol ® ATO 5 Vehículos Oleosos. However with a higher melting point and longer fatty acid chains it can have a release retarding effect when used at high concentration. Gelucire® 48/16, a novel carrier available in powder and pellet forms, is PEG-32 stearate, while, conventional gelucires, Gelucire® 44/14 and Gelucire® 50/13 are lauroyl polyoxyl-32glycerides NF and stearoyl polyoxyl-32 glycerides NF respectively.

USB1 US09/623,213 USA USB1 US B1 US B1 US B1 US A US A US A US B1 US B1 US B1 Authority US United States Prior art keywords aqueous dispersion acid plasticizer lt dosage form Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. It is composed of fatty acid (majority of C 16 and C 18) esters of glycerol, PEG esters and free PEG. Lipid binder in melt processes.

GELUCIRE 50/13 and GELUCIRE 53/10 can be used according to our invention, but GELUCIRE 50/13 has been found to be particularly effective. Application of Acconon C-50® and Gelucire 50/13® as Both Solidifying and Emulsifying Agents for Medium Chain Triglycerides Journal of Excipients and Food. This can be advantageous for certain drugs or peptides and in.

The two numbers of Gelucires show their melting points and HLB values, respectively. Different mixtures of the lipid and each solidifying agent were heated to 65ºC until homogenously mixed clear liquids were formed. Labrafil® series (Table 2) consist of self-emulsifying excipients that may be in SEDDS / SMEDDS.

Preparation of solid dispersions (SDs) and physical mixtures (PMs) Solubility enhancement of glibenclamide. Mejoradores de la Biodisponibilidad. The effect of variation in the Gelucire 50/13 concentration on the particle size of the Precirol SLN was also evaluated.

BAIJUDIER, PHILIPPE, SERVAIS, CECILIE, VANDERBIST, FRANCIS. Gelucire 39/01 y 43/01;. Semi-solid bioavailability enhancer and sustained release agent.

Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS). Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS). Functionality Solubilizer for poorly-soluble APIs and bioavailability enhancer.

Solid self-emulsifying drug delivery systems (SEDDS) for medium chain triglycerides (Captex® 355, ABITEC) were developed using stearoyl polyoxyl glycerides (Acconon® C-50, ABITEC and Gelucire® 50/13, Gattefosse) as both solidifying and emulsifying agents. Other products, such as. Dissolution studies were performed for melt granules of AET with Gelucire 50/13 (MG-AET) and solid dispersion with PVP (SDP) to differentiate dissolution performance.

Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS). Between gelucire 50/13 and poloxamer 1 and to formulate the optimized solid dispersion into immediate release tablets. A number of systems were prepared at five compositions (5, 10, , 30 and 40% w/w) of diclofenac/N-(2-hydroxyethyl) pyrrolidine salt and acidic diclofenac in PEG6000 and Gelucire 50/13, as.

Main components of Gelucire® 50/13. The average particle size of Gelucire 43/01 beads were not affected significantly by increasing Gelucire 43/01 ratio. It is able to self-emulsify on contact with aqueous media forming a fine dispersion i.e.

MATERIALS and METHODS Materials Bosentan was received as gift sample from MSN Pharma, India. A mean particle size of approximately 250 nm was obtained for PVP K30-sirolimus nanoparticles. Legal notice - Terms and condition © Gattefossé People make our name.

The formulation with labrafil or Gelucire® 50/02 are too lipophilic to give a good dissolution in water. Plurol Oleique ® CC497;. The use of stearoyl macroglyceride (Gélucire® 50/13, Gattefosse) and soyabean oil allows to obtain a formulation with a dissolution profile similar to the reference (Roaccutane® mg, Roche).

Solubilizer for poorly-soluble APIs and bioavailability enhancer. Several of these products listed are liquid or semi-solid, hence suitable for soft or hard shell capsules. Single excipient formulation system:.

Gelucire 50/13, and Gelucire 43/01 as lipid carriers. Modulation of drug release. Single excipient formulation system:.

Modulation of drug release. Gelucire 33/01, 39/01 y 43/01… Capryol ™ PGM Y 90;. Its chemical name is Stearoyl macrogol-32 glycerides.

Gelucire ® 50/13, Gattefosse) may serve as both. Lipid binder in melt processes. Gelucire ® 50/13 It is a non-ionic, water dispersible surfactant composed of well-characterized PEG-esters, a small glyceride fraction and free PEG.

Self-emulsifies in aqueous fluid into coarse emulsion—LFCS Type III (SMEDDS). R=C16 or C18 Schematic structures PEG1500 esters O H R -C O -O 3 3 O -C O -R R -C O -O 3 3 Phospholipon® 90G Phospholipon® 90G was received as a gift sample from Phospholipid GmbH (Nattermannalle, Germany). 50 °C and HLB 13.

Sol id if yi ng an d emu ls if yi ng age nt s for. Solubilizer for poorly-soluble APIs and bioavailability enhancer. Application of Acconon C-50 and Gelucire 50/13 as Both Solidifying and Emulsifying Agents for Medium Chain Triglycerides.

Gelucire® 44/14, Gelucire® 48/16, Gelucire® 50/13. Application Water dispersible surfactant, Solubilizer, Bioavailability enhancer, Component of SELF, Matrix for modified release, Multiparticulates;. Gelucire® 50/13 is a well characterized excipient, supported by numerous publications and worldwide precedence of use including FDA IID listing.

One preferred BCS class II drug is TEL. Gelucires 44/14 (lauroyl macroglycerides), 50/13 (stearoyl macroglycerides), 62/05 (glyceryl behenate), and Labrasol were supplied by Gattefossé (Saint-Priest cedex, France). Gelucire 50/13 is an excipient composed of fatty acid (C16 and C18) esters of glycerol, PEG esters and free PEG.

Ranitidine HCl– lipid granules were prepared by the melt granulation technique and evaluated for in vitro floating and drug release. Modulation of drug release. Effect of variation in the Gelucire 50/13 concentration.

The dissolution of poorly water soluble drugs may be significantly enhanced in a solid dispersion with hydrophilic lipid excipients, such as Gelucire 50/13 (85), Gelucire 44/14 (,93) compared to. Self-emulsifies in aqueous fluid. Lipid binder in melt processes.

Lauroglycol ™ FCC Y 90;. Gelucire 50/13 was received as gift sample from Gattefosse, India, Poloxamer 1 was procured from Sigma Aldrich, India. Gelucire ®50/13 (Stearoyl macrogol-32 glycerides) - bioavailability enhancement and sustained release Labrafil ®M2125 CS (Linoleyl macrogol-6 glycerides) - bioavailability enhancement Labrafil.

Curcumin (CUR), Tween® 85 and Tween® 80 were purchased by Sigma Aldrich (Milan, Italy). Journal of Excipients and Food Chemicals , S.l., v. Labrasol®, Gelucire® 44/14, Gelucire® 48/16, Gelucire® 50/13 and the Labrafil® series (Table 2) consist of self-emulsifying excipients that may be in SEDDS / SMEDDS.

All other materials and reagents were of analytical grade of purity. Several of these products listed are liquid or semi-solid, hence suitable for soft or hard shell capsules. The excipient is primarily a mix-ture of PEG 1500 mono- and diesters with.

Gelucire® 44/14 has achieved official USP-NF status with pending Food Additive (FCC) status. The aim of this study was to develop a formulation containing fenofibrate and Gelucire(®) 50/13 (Gattefossé, France) in order to improve the oral bioavailability of the drug. N,O -CMCS (deacetylation degree 92.8%), was purchased from Heppe Medical Chitosan GmbH Halle (Saale), Germany and, according to manufacturer instructions, possesses a molecular weight in the.

The average particle diameter of beads was found to be in the size range of 3.85 ± 0.13, 3.95 ± 0.21, and 3.87 ± 0.18 mm with varying drug/Gelucire 43/01 ratio from 1:5, 1:10, and 1:15, respectively (Table I). Gelucire® 44/14 is a versatile semi-solid lipidic excipient, proven to improve the bioavailability of poorly soluble drugs. All other materials and reagents used were of analytical grade.